1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Peregrine Pharmaceuticals (NASDAQ:PPHM) Investor Alert: Lawsuit alleges Misleading Statements

A lawsuit was filed for certain investors in shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) shares over alleged securities laws violations. Deadline: November 27, 2012 and NASDAQ:PPHM stockholders should contact the Shareholders Foundation.

 
 
mail@shareholdersfoundation.com
mail@shareholdersfoundation.com
PRLog - Oct. 15, 2012 - An investor in shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) filed a lawsuit in the U.S. District Court, Central District of California against Peregrine Pharmaceuticals over alleged securities laws violations in certain allegedly false and misleading financial statements.

If you purchased shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) between July 17, 2012 and September 26, 2012, you have certain options and there are short and strict deadlines running. Deadline: November 27, 2012. NASDAQ:PPHM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of all persons who purchased Peregrine Pharmaceuticals (NASDAQ:PPHM) common stock between July 17, 2012 and September 26, 2012, that Peregrine Pharmaceuticals and certain of its officers violated the Securities Exchange Act of 1934 by issuing between July 17, 2012 and September 26, 2012 allegedly materially false and misleading statements regarding Peregrine Pharmaceuticals’ Bavituxmab Phase II Second-Line Non-Small Cell Lung Cancer Trial.

Specifically, so the plaintiff, Peregrine Pharmaceuticals allegedly made false and/or misleading statements and/or failed to disclose that there were major discrepancies between some patient sample test results and patient treatment code assignments in the Company's Phase II Trial.

On September 24, 2012 Peregrine Pharmaceuticals announced that it had discovered major discrepancies in treatment group cofding by an independent third-party vendor responsible for distribution of blinded investigational product used in its bavituximab phase II second-line non-small cell lung cancer trial.

Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) dropped from $5.36 per share on September 21, 2012 to as low as $0.99 on September 28, 2012.

Those who purchased shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) between July 17, 2012 and September 26, 2012, have certain options and there are short and strict deadlines running. Deadline: November 27, 2012. NASDAQ:PPHM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Photo:
http://www.prlog.org/11999142/1

--- End ---

Click to Share

Contact Email:
***@shareholdersfoundation.com Email Verified
Source:Shareholders Foundation, Inc.
Phone:+1-(858)-779-1554
Zip:92108
City/Town:San Diego - California - United States
Industry:Business, Finance
Tags:Peregrine Pharmaceuticals, NASDAQ:PPHM, securities class action, class action, lawsuit
Shortcut:prlog.org/11999142
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share